MW Ozempic maker's stock surges. A trial of a new Novo Nordisk drug shows promise.
By Steve Goldstein
Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much as 22%.
Novo Nordisk said a Phase 1b/2a clinical trial of amycretin, which activates both the GLP-1 and amylin receptors to help manage blood sugar and weight, achieved weight loss of 22% on a 20 milligram once-per-week dose taken for 36 weeks.
This trial was done by injecting patients - which is how popular drugs Ozempic and Wegovy are administered - but it's also being developed for oral administration.
It said most of the side effects were gastrointestinal and mild to moderate in severity.
Novo Nordisk said it is now planning further clinical development of amycretin in adults with overweight or obesity.
Novo Nordisk stock (DK:NOVO.B) $(NVO)$ rallied 12% in Copenhagen trade, though it's still down about 13% from where it was after a disappointing trial of CagriSema.
-Steve Goldstein
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
January 24, 2025 08:47 ET (13:47 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。